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DOI 10.1002/ajmg.a.36431Metaphyseal dysplasia, Spahr type (MDST; OMIM 250400) was
described in 1961 based on the observation of four children in
one familywhohad rickets-likemetaphyseal changes but normal
blood chemistry and moderate short stature. Its molecular basis
and nosologic status remained unknown. We followed up on
those individuals and diagnosed the disorder in an additional
member of the family. We used exome sequencing to ascertain
theunderlyingmutationand explored its consequenceson three-
dimensional models of the affected protein. The MDST pheno-
type is associated with moderate short stature and knee pain in
adults, while extra-skeletal complications are not observed. The
sequencing showed that MDST segregated with a c.619T>G
single nucleotide transversion in MMP13. The predicted non-
conservative amino acid substitution, p.Trp207Gly, disrupts a
crucial hydrogen bond in the calcium-binding region of the
catalytic domain of the matrix metalloproteinase, MMP13.
TheMDSTphenotype is associatedwith recessiveMMP13muta-
tions, confirming the importance of thismetalloproteinase in the
metaphyseal growth plate. Dominant MMP13 mutations have
been associatedwithmetaphyseal anadysplasia (OMIM602111),
while a single childhomozygous for aMMP13mutationhadbeen
previously diagnosed as “recessive metaphyseal anadysplasia,”
that we conclude is the same nosologic entity as MDST. Molecu-
lar confirmation ofMDSTallows distinction of it fromdominant
conditions (e.g., metaphyseal dysplasia, Schmid type; OMIM #
156500) and frommore severe multi-system conditions (such as
cartilage-hair hypoplasia; OMIM # 250250) and to give precise
recurrence risks and prognosis.  2014 Wiley Periodicals, Inc.
Key words: metaphyseal dysplasia; Spahr dysplasia; MMP13;
metalloproteinase; exome sequencing2014 Wiley Periodicals, Inc. 1
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In 1961, Andre´ and Ines Spahr described a family from the Swiss
Canton of Valais in which four of five siblings had moderate short
stature, mild genua vara, and radiographic signs of metaphyseal
dysplasia, but no biochemical signs of rickets [Spahr and Spahr-
Hartmann, 1961]. Normal height parents and the high consan-
guinity rate in the village of origin of that family suggested a
recessively inherited metaphyseal dysplasia. The condition became
known as metaphyseal dysplasia, Spahr type (MDST) and was
included in the OMIM catalog (OMIM 250400) as well as in the
Nosology of Genetic Skeletal Disorders since 1970 [Warman
et al., 2011]. It is very rare, with only two reports following the
original one [Farag and Teebi, 1990; Megarbane et al., 2008].
Having access to the original family described in 1961, we set
out to obtain a clinical follow-up as well as DNA samples from
selected family members to explore its molecular basis.MATERIALS AND METHODS
We studied DNA from the original family reported by Spahr and
Spahr-Hartmann [1961] (Fig. 1). The study was conducted within
the frame of a Swiss National Foundation-funded research project
on chondrodysplasias forwhich ethical approvalwas obtained from
the State Ethics Committee (Canton Vaud). Informed consent was
obtained from affected individuals and their relatives, and blood
was drawn into EDTA tubes and DNA extracted by standard
procedures. In a first series of experiments, the exons and in-
tron/exon boundaries ofCOL10A1 andRMRP (mutations inwhich
cause metaphyseal chondrodysplasia, Schmid type (MCS) [War-
man et al., 1993] and cartilage-hair hypoplasia (CHH) [Bonafe
et al., 2002], respectively) were sequenced. Subsequently, the DNA
of two affected (II-6, III-1) and one unaffected, obligate carrier
individuals (I-3) were subjected to exome sequencing using pub-FIG. 1. Pedigree and sequence data from the family with MDST. Black sy
clinically unaffected individuals. Individuals II-3 to II-7 correspond to the
subsequently. “ES” denotes the three individuals, whose DNA has been s
indicate the results obtained by Sanger-type PCR sequencing of affectedlished protocols [Shi et al., 2011]. The results were analyzedwith an
informatics pipeline excluding variants present at significant fre-
quency in public databases, as well as variants frequently observed
in the in-housedatabase.Resultswere further prioritized in termsof
data quality and, most significantly, assuming homozygosity by
descent in the two affected individuals and heterozygosity in the
obligate carrier. Candidate mutations were screened using known
annotations for gene function and associated phenotypes.
Sanger sequencingwas used to validate the presence and status of
this mutation in the individuals included in the original exome
sequencing study as well as in five other obligate carriers in the
pedigree.RESULTS
Clinical Follow-up
The original family comprised one unaffected and four affected sibs
(Fig. 1). Of the four affected sibs, one was deceased because of an
accident. The female Individual II-6was followedup at age 47 years.
Her adult heightwas138 cm, andherweightwas53 kg. Shehadbeen
professionally active as a secretary and had not founded a family.
She was in good general health but reported recurrent knee pain.
Magnetic resonance studies were reported to show significant knee
arthritis with osteochondritis dissecans and presence of intra-
articular free bodies. Her older brother, individual II-5, was
reported tobe167 cmtall.Hewasprofessionally active, hadmarried
and had children. The younger brother, individual II-7, was
reported tomeasure 150 cm. He had notmarried. Neither reported
chronic health problems.
Several years after the first report on MDST in 1961, we diag-
nosed the same disorder in a first cousin once removed of the
original sibs (Individual III-1 in the pedigree, Fig. 1). This female
individual, born in 1971, came to medical attention at age sevenmbols denote individuals diagnosed with MDST, white symbols denote
sibship described in the original paper. Individual III-1 was diagnosed
ubjected to exome sequencing. The indications below the symbols
and unaffected individuals. N.A., sample not available.
BONAFE´ ET AL. 3years because of short stature and intermittent knee pain. Her
parents heights were 167 cm (father) and 155 cm (mother), giving
her a target height of approximately 155 cm. Her height at age
7 years was at 2.5 SD, and her growth curve remained below
the third centile, but parallel to it, until age 13 when she was lost
to follow up. Radiographs at age 7 years showed metaphyseal
dysplasia. When re-contacted at age 31 years, her height was
150 cm (thus only 5 cm below her genetic target height), her weight
54 kg. She no longer complained of knee pain. She had trained and
worked as a nurse and had one healthy child.Molecular Findings
No mutation was found in the COL10A1 and RMRP genes, first
candidates for this metaphyseal dysplasia.
Upon inspection of the filtered data from exome sequencing,
only one mutation met the criteria of correct segregation and low
frequency on control datasets: a c.619T>G transversion which
predicts p.Trp207Gly in the MMP13 protein (nucleotide
102824903 of chromosome 11, A>C; Ensembl transcript
ENST00000571284, MMP13, c.619T>G). Sanger sequencing con-
firmed homozygosity in the two affected individuals, and hetero-
zygosity in all obligate carriers (see pedigree in Fig. 1).FIG. 2. Molecular pathology of MMP13. A: simplified scheme of the MMP1
located in the propeptide domain. The recessive mutations (in orange) p
seen in a single patient, are in the catalytic domain. B: Crystal structure
present in the structure has been removed for simplicity). The mutated r
histidines (H222, H226, H232) coordinating the catalytic zinc ion are in
are white spheres. C: Close view on the Trp207 (W207) residue in the vic
hydrogen bond (black dotted line, HB1) with the carbonyl oxygen of D20
of W207 forms a hydrogen bond (HB2) with D128, which coordinates anoResidue Trp207 is highly conserved both across species and
between different human MMPs (data not shown). The SIFT,
POLYPHEN and PROVEAN programs predict the substitution
p.Trp207Gly to be damaging (SIFT score: 0, POLYPHENHumVar
score: 1.00, PROVEAN score:10.091). As fresh-frozen plasma or
cultured cells for assessment of MMP13 activity were unavailable,
we used molecular modeling to study the position and role of the
affected residue, Trp207, within MMP13. The results are depicted
in Figure 2. The catalytic site of MMP13 is lined by three histidine
residues (His222, His226, and His232) that coordinate the zinc
atom. Residue Trp207 is buried in the core of the catalytic domain,
and its bulky hydrophobic character is likely necessary to maintain
the proper architecture of the protein and to prevent misfolding. A
glycine in the samepositionwouldnot be able to fulfill the same role
as the tryptophan due to lack of a side chain. In addition, the two
hydrogen bonds formed by Trp207 support residues Asp202 and
Asp128 that coordinate the structural calcium ions. A substitution
to glycine would result in the loss of one of the hydrogen bonds,
which would likely diminish the stability of the protein fold.
Thec.619T>Gsequencechangewasabsent inover100 local control
individuals. Interestingly, this change (that has no clinical consequen-
ces at heterozygosity, as the molecularly proven carriers in the family
haveanormal skeletalphenotype)accounted for twoofapproximately3 protein with its domains. The dominant mutations (in red) are
.Trp207Gly, as found in the family reported here, and p.His232Asn,
of MMP13 (PDB entry 3ZXH) in cartoon representation (the inhibitor
esidue Trp207 (W207) is shown as purple sticks, and the three
dark blue. Zinc ions are depicted as cyan spheres, and calcium ions
inity of two Ca2þ binding sites. The side chain of W207 forms a
2, which coordinates one of the calcium ions. The main chain nitrogen
ther calcium ion.
4 AMERICAN JOURNAL OF MEDICAL GENETICS PART A13,000 unselected alleles included in the Washington University
Exome Variant Server (http://evs.gs.washington.edu/) cohort, giving
it an allelic frequency of approximately 0.00015; such a frequency is in
the range of a very rare recessive allele.DISCUSSION
The exome analysis and the subsequent direct PCR sequencing
study showed that the two affected individuals were homozygous
andunaffectedobligate carriers heterozygous for a single nucleotide
transversion predicting a p.Trp207Gly substitution in MMP13.
Even in absence of experimental functional data, the genetic evi-
dence (segregation in the family and rarity in control alleles), the
molecular modeling, and the prediction data strongly suggest that
p.Trp207Gly is pathogenic in this family andnot a harmless variant.
Mice in whom the mmp13 has been inactivated display
a disturbed structure of the metaphyseal growth plate [Stickens
et al., 2004], linking cartilage matrix degradation to the prolifera-
tionof chondrocytes at the growth plate. In humans, themajority of
MMP13 mutations act as dominant negative and result in meta-
physeal anadysplasia [Lausch et al., 2009]. TheMMP13 protein has
threemain domains; the pro-domain, the catalytic domain, and the
C-terminal domain with four hemopexin-like subdomains [Lee-
man et al., 2002] (see http://www.uniprot.org/uniprot/P45452 for
details). The more common MMP13 mutations associated with
dominant metaphyseal anadysplasia [Lausch et al., 2009], as well as
a further dominant mutation associated with spondylo-metaphy-
seal dysplasia [Kennedy et al., 2005], are located in the propeptide
domain (Fig. 2A). By disrupting the tertiary structure of the
propeptide domain, they result in premature activation of the
proteinase, which in turn determines autocatalytic self-inactivation
of MMP13 as well as in heterocatalytic inactivation of the related
enzyme, MMP9 [Lausch et al., 2009]. The catalytic region of
MMP13 is situated in the central portion of the molecule: amino
acids 172 to 232 include all calcium-binding and zinc-binding
residues necessary for catalysis (Fig. 2A). In the previous study,
we had observed a child who was homozygous for a mutation in
MMP13 and we had given him the diagnosis of recessive meta-
physeal anadysplasia [Lausch et al., 2009]. TheMMP13mutation in
that child, p.His232Asn, affected the histidine residue at position
232 involved in zinc binding [Lausch et al., 2009]. The novel
mutation segregating in the present MDST family, p.Trp207Gly,
affects a residue involved in the stabilization of the calcium-binding
region (Fig. 2B and C). Together, the data suggest that the pheno-
type ofMDST is associatedwith homozygosity for a loss of function
mutation in MMP13 and that the one child with “recessive meta-
physeal anadysplasia” can be retrospectively diagnosed as MDST.
As we failed to recognize this phenotypic similarity, we did not
analyze MMP13 and MMP9 directly, but took the more complex
strategy of exome sequencing. On the positive side, the exome
approach is unbiased and adds significance to our findings.
Although the follow-up of affected individuals in this and in the
previous study [Lausch et al., 2009] was limited, we conclude that
MDST is associated with short stature of variable degree: the
shortest affected patient was II-6, a female with a final height of
138 cm, and the tallest individuals was II-5, reported to be 167 cm
tall. Individual II-6 also suffered from knee joint degeneration,whilePatient III-1hadhadkneepain in childhoodbutwas free from
symptoms in adulthood. Otherwise, no other significant symptom
or clinical signwas reported.Wewould also conclude thatMDST is
possibly, but not consistently, associated with knee pain in child-
hoodand/or early-onset degenerative arthritis of the knee, although
the latter findingmaybe coincidental as it was present in only one of
the five adult individuals.
The prognostic implications are quite different in the different
conditions with metaphyseal dysplasia, for example, MCS [War-
man et al., 1993] (OMIM # 156500), CHH [Bonafe et al., 2005]
(OMIM # 250250), or dominant metaphyseal anadysplasia (MAD;
OMIM # 602111). Are there criteria that allow for a differentiation
between these disorders? The clinical presentation of MDST is
similar to that of MCS, with normal length at birth, bowing and
shortening of the legs becoming apparent after the child begins to
stand, and a waddling gait. In contrast, patients with CHH are
usually short at birth or display growth failure already in the first
months of life; their adult height is significantly shorter than in the
two other conditions. Patients with CHH also present with varus
deformity of the lower limbsbut this is usually less pronounced than
in patients withMCS orMDST and waddling gait is rare. Themain
distinctive clinical features of patients with CHH are short hands
and feet and joint laxity, which are not found in the two other
conditions. The presence of sparse hair and immune deficiency or
anemia are not obligate diagnostic criteria of CHH as about 30% of
patients present only the skeletal features of the disease. However,
even in the “isolated skeletal variant” of CHH [Bonafe et al., 2002]
there seems to be a persistent risk of hematopoietic cancer at young
adult age,which is not the case for patientswithMDSTorMCS.The
facial appearance is normal in all three conditions.
Radiographic features include metaphyseal dysplasia mostly
prominent at the lower limbs in all three conditions; while the distal
femoral and proximal tibia metaphyses are involved in all three, the
varus deformity typical for MCS is absent or less pronounced in
MDST. In CHH, the femoral neck is often constricted and distinct
fromMDST andMCS. The capital femoral epiphyses are rather large
in MCS during childhood, whereas they are of small size in MDST.
The radiographic appearanceof spine andpelvis is normal inall three
conditions althoughmild platyspondyly may be seen occasionally in
MCS. The differentiation ofMDSTandMADmay bedifficult, as the
conditions are almost superimposable, the main difference being in
stature:whileMDSTisassociatedwithshort stature inchildhoodand
in adulthood, the height of individuals affected by the dominantly
inheritedMAD is usually between1 and2 SD. Finally, spondylo-
epi-metaphyseal dysplasia (SEMD) Missouri type is a condition
reported in a single family associated with a dominant mutations
(p.Phe56Ser) inMMP13 located in the prodomainof the protein; the
metaphyseal involvement has been reported in combination with a
mild degree of vertebral involvement [Kennedy et al., 2005]. How-
ever, a very similar mutation (p.Phe55Ser vs. p.Phe56Ser) has been
repeatedly observed in dominant MAD, and the biochemical con-
sequences of the two mutations appear to be the same [Lausch
et al., 2009], suggesting that inpractical terms, the two conditions are
indistinguishable. In summary, MDST, a recessive entity, should be
readily distinguishable fromCHH,while distinction fromMCDand
fromMADwouldrequire either thepresenceofadominantpedigree,
or molecular genetic testing.
BONAFE´ ET AL. 5Besides unraveling the molecular basis of a disorder described
more than 50 years ago and filling a gap in the Nosology of genetic
bone disease [Warman et al., 2011], the results demonstrate that the
observation of metaphyseal dysplasia in an infant and small child
requires careful differential diagnosis. With next generation
sequencing rapidly entering the diagnostic scene, the availability
of documented genotype-phenotype correlations, such as the one
presented here, will be of crucial importance in providing families
and physicians with information on diagnosis and prognosis.ACKNOWLEDGMENTS
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